Bide Pharmatech Co., Ltd. (SHA:688073)
China flag China · Delayed Price · Currency is CNY
76.60
+2.32 (3.12%)
At close: Sep 30, 2026

Bide Pharmatech Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,3791,3241,1021,092833.8606.05
Other Revenue
0.0500.010.030.030.17
1,3791,3241,1021,092833.83606.22
Revenue Growth
15.18%20.13%0.93%30.95%37.55%54.86%
Cost of Revenue
766.68773.33680.35673.38471.29315.89
Gross Profit
612.44550.48421.66418.48362.54290.33
Selling, General & Admin
296.56293.96244.87250.12167.26145.16
Research & Development
62.1159.4455.6259.7243.4632.1
Other Operating Expenses
15.395.276.435.013.962.42
Operating Expenses
377.06362.81308.68319.18218.2182.75
Operating Income
235.38187.67112.9999.3144.34107.58
Interest Expense
-4.33-5.8-3.32-2.53-2.16-0.92
Interest & Investment Income
18.0519.3423.7431.748.863.9
Currency Exchange Gain (Loss)
-40.5-17.944.995.9312.55-6.67
Other Non Operating Income (Expenses)
-2.92-2.11-4.12-2.5-2.23-1.08
EBT Excluding Unusual Items
205.68181.17134.28131.95161.35102.8
Gain (Loss) on Sale of Investments
3.490.673.15-12.63-0.46-
Gain (Loss) on Sale of Assets
8.413.91.150.44-7.92
Asset Writedown
-1.11-1.11-0.03-0-0-0.04
Other Unusual Items
15.0810.819.466.2510.883.87
Pretax Income
231.54195.43148.02126171.77114.56
Income Tax Expense
49.943.6930.5917.5525.816.99
Earnings From Continuing Operations
181.64151.74117.43108.45145.9797.57
Minority Interest in Earnings
---1.13--
Net Income
181.64151.74117.43109.57145.9797.57
Net Income to Common
181.64151.74117.43109.57145.9797.57
Net Income Growth
30.68%29.22%7.17%-24.94%49.60%65.37%
Shares Outstanding (Basic)
868789917467
Shares Outstanding (Diluted)
878889917467
Shares Change
-0.62%-1.40%-1.76%22.83%10.09%8.03%
EPS (Basic)
2.111.751.321.211.981.46
EPS (Diluted)
2.081.731.321.211.981.46
EPS Growth
31.49%31.06%9.09%-38.89%35.89%53.38%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
81.534.0469.97-118.47-8.54-94.09
Free Cash Flow Per Share
0.930.050.79-1.31-0.12-1.41
Dividend Per Share
1.1601.1600.9000.9001.100-
Dividend Growth
28.89%28.89%0%-18.18%--
Gross Margin
44.41%41.58%38.26%38.33%43.48%47.89%
Operating Margin
17.07%14.18%10.25%9.09%17.31%17.75%
Profit Margin
13.17%11.46%10.66%10.04%17.51%16.10%
Free Cash Flow Margin
5.91%0.30%6.35%-10.85%-1.02%-15.52%
EBITDA
250.38201.88124.12108.85150.15111.51
EBITDA Margin
18.15%15.25%11.26%9.97%18.01%18.39%
D&A For EBITDA
15.0114.2111.139.555.813.93
EBIT
235.38187.67112.9999.3144.34107.58
EBIT Margin
17.07%14.18%10.25%9.09%17.31%17.75%
Effective Tax Rate
21.55%22.36%20.67%13.93%15.02%14.83%
Revenue as Reported
1,3791,3241,1021,092833.83606.22
Advertising Expenses
-8.189.597.775.655.87